Leqembi (Lecanemab-irmb) Medical Benefit Drug Policy — Coverage Criteria for Early Alzheimer's Disease
Policy governing medical benefit drug coverage of Leqembi (lecanemab-irmb) for treatment of early Alzheimer's disease (mild cognitive impairment or mild dementia) including initial and continuation authorization criteria and required documentation for UnitedHealthcare commercial plans.
Revised coverage criteria: Initial Therapy - Removed criterion requiring attestation that the patient does not have access to amyloid PET scanning; replaced diagnosis language to 'mild dementia due to Alzheimer's disease'.
Changed MMSE threshold for submission of medical records from 22 or greater to 20 or greater for initial and continuation therapy.
Reauthorization interval changed from no more than 6 months to no more than 12 months.
Updated examples of other amyloid-beta monoclonal antibodies that must not be given in combination with Leqembi; added Kisunla.
Added Benefit Considerations section (template update).
Coverage Criteria for Leqembi (lecanemab-irmb)
Initial Therapy
Covered when ALL of the following are met for initial therapy:
See chunks 3 and 4 for diagnostic language.
See chunk 4.
See chunk 4.
See chunk 4.
See chunk 4.
See chunks 4 and 5.
See chunk 5.
See chunk 5.
See chunk 5.
See chunks 4 and 5.
See chunk 5.
See chunk 5.
Continuation Therapy
Continued coverage when ALL of the following are met:
See chunk 5.
See chunk 6.
See chunk 6.
See chunk 6.
See chunk 6.
See chunk 6.
See chunk 6.
Not Medically Necessary / Unproven
See chunk 6.
Initial Therapy (revised criteria reflected in policy changes)
Covered when ALL of the following are met (summary of revised criteria present in policy history):
Reflects revised diagnostic language in policy history (chunks 30–32).
MMSE threshold revised from ≥22 to ≥20 (chunks 31–32).
See chunks 31–32.
See chunks 31–32.
See chunks 31–32.
Continuation Therapy / Reauthorization (revised)
Covered for continuation when ALL of the following are met:
See chunks 31–32.
MMSE threshold revised (chunks 31–32).
See chunks 31–32.
Reauthorization interval changed from 6 to 12 months (chunk 32).
Leqembi must not be administered in combination with other anti–amyloid-beta monoclonal antibodies. Examples listed in the policy include Aduhelm and the recently added example Kisunla. Concurrent use with other AB-directed mAbs is an exclusion to coverage and will result in noncoverage per policy.
The policy explicitly excludes members who are receiving other specified amyloid‑beta monoclonal antibodies concurrently with Leqembi. The revised examples of prohibited concurrent agents include Aduhelm and now list Kisunla as an additional example of an anti‑amyloid mAb that must not be given concurrently with Leqembi.
Leqembi is considered unproven and not medically necessary for any indication outside the population studied and intended for treatment — that is, it is not supported for uses beyond mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. FDA labeling and the policy limit initiation to the early AD population enrolled in the pivotal trials.
Use of Leqembi outside the indicated population (patients who do not have early Alzheimer’s disease, i.e., MCI or mild dementia) or without documentation of biomarker evidence of beta‑amyloid deposition (positive amyloid PET or qualifying CSF biomarker results) is not supported by the clinical evidence in this policy and is therefore not covered.
Coding and Clinical Score Thresholds
| J0174 | Injection; lecanemab-irmb, Img |
| G30.0 | Alzheimer's disease with early onset |
| G30.1 | Alzheimer's disease with late onset |
| G30.8 | Other Alzheimer's disease |
| G30.9 | Alzheimer's disease, unspecified |
| affected codes | placeholder for drug administration, J-codes, and related CPT/HCPCS used for Leqembi; document references that specific codes are affected but does not list them in this excerpt. |
Prior Authorization, Documentation, and Utilization Management
Prior Authorization Required
Prior authorization is required for initiation and continuation of therapy. Initial authorization is limited to no more than 6 months; reauthorization (continuation) is limited to no more than 12 months.
- Prior authorization required before dispensing or scheduling treatment
- Initial authorization: ≤ 6 months
- Reauthorization/continuation: ≤ 12 months
Documentation Must Meet Coverage Criteria
Documentation submitted with the prior authorization request must meet the revised coverage criteria, including diagnosis language updates, cognitive assessment thresholds, and amyloid biomarker evidence.
- Diagnosis documented as mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia
- MMSE documented ≥ 20
- Evidence of beta-amyloid deposition (positive amyloid PET or CSF biomarker abnormalities)
Required Documentation for Initial and Continuation Authorization
Submit required clinical documentation for both initial and continuation authorization. Updated assessments for continuation must be measured no earlier than 4 weeks prior to the continuation request.
- Medical records/chart notes and laboratory values documenting diagnosis and assessments
- Global CDR score of 0.5 or 1.0 and CDR Memory Box score ≥ 0.5
- MMSE ≥ 20; MoCA ≥ 17 or SLUMS ≥ 17 as alternative cognitive scores
- Documentation of beta-amyloid evidence (positive amyloid PET or CSF biomarker testing)
- Baseline brain MRI and medical records confirming follow-up MRI after initiation for ARIA monitoring
Denial Risk for Incomplete Documentation
Failure to submit required medical records—such as documentation of diagnosis, cognitive scores, amyloid biomarker evidence, baseline MRI, or required follow-up MRI—may result in denial of the request.
- Missing MMSE, CDR, or biomarker evidence increases denial risk
- Absence of baseline or follow-up MRI documentation may lead to denial
Member-Specific Benefit Verification
Use member-specific benefit verification to determine whether the service is covered for a particular member. In the event of any conflict, the member-specific benefit plan document governs the coverage decision.
- Verify eligibility and benefits against the member-specific plan document before submitting a prior authorization request
- If state or federal mandates apply, follow those requirements as applicable
Utilization Management Tools
Policy requirements may be used alongside other utilization management tools. UnitedHealthcare may also use third-party tools (for example, InterQual) to assist in administering benefits.
- Policy determinations should be coordinated with other UM tools and program rules
- Third-party criteria (e.g., InterQual) may be applied as part of benefit administration
Provider Action
Provider action: verify member benefits, assemble and submit all required documentation, and ensure continuity with utilization management tools as applicable.
- Verify member-specific benefits and coverage rules prior to authorization submission
- Assemble required clinical records (scores, biomarker evidence, baseline and follow-up MRIs)
- Coordinate with UM programs or third-party tools when requested
Background on Alzheimer's Disease and Lecanemab
Alzheimer’s disease is a progressive neurodegenerative disorder characterized pathologically by accumulation of amyloid‑beta (Aβ) plaques and tau neurofibrillary tangles, which correlate with neuronal loss and cognitive decline. Therapies that target aggregated amyloid‑beta, such as Leqembi (lecanemab‑irmb), are intended to reduce amyloid burden; clinical trials (including CLARITY AD and Study 201) evaluated Leqembi in patients with early Alzheimer’s disease (mild cognitive impairment or mild dementia) and required biomarker confirmation of Aβ pathology. Trial data showed reductions in brain amyloid and mixed results on clinical endpoints, and treatment carries risks such as amyloid‑related imaging abnormalities (ARIA‑E/ARIA‑H), which require baseline and follow‑up MRI monitoring and informed shared decision‑making.
Definitions and Clinical Scales
Policy Revision History and Material Changes
Initial Therapy criteria revised: removed requirement for attestation regarding access to amyloid PET and replaced diagnosis language with 'mild dementia due to Alzheimer's disease'.
MMSE threshold for initial and continuation therapy changed from 22+ to 20+; reauthorization interval changed from no more than 6 months to no more than 12 months; examples of other amyloid-beta monoclonal antibodies updated to add Kisunla.
Template updated and Benefit Considerations section added (template-only update).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.